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Abstract
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. Based on
literature reports of limited cases, over 50 % of BPDCN have chromosomal abnormalities, but no single chromosomal
change has been identified as diagnostic of this entity.
Case presentation: In this report, we present a case of BPDCN with complicated chromosomal abnormalities
involving chromosomes 12 and 22 and resulting in a simultaneous partial deletion of ETV6 and EWSR1. Notably, these
aberrations were identified in bone marrow myeloid precursors in the absence of bone marrow involvement by
BPDCN.
Conclusion: Analysis of 46 BPDCN cases with abnormal karyotypes (45 from literature reports plus this case) showed
that 12p- is one of the most common structural aberrations in BPDCN. The ETV6 and CDKN1B on 12p deserve further
investigations as potential markers of BPDCN.
Keywords: Blastic plasmacytoid dendritic cell neoplasm (BPDCN), Karyotype, Chromosomal abnormality, 12p-, ETV6,
CNKN1B, EWSR1
Background
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a
rare, aggressive myeloid neoplasm derived from plasmacy-
toid dendritic cells [1]. This disease has been previously
described in the past using terms such as “acute agranular
CD4+ natural killer (NK) cell leukemia” [2], “blastic NK cell
lymphoma” [3] and “agranular CD4 +CD56+ hematoder-
mic neoplasm/tumor” [4, 5]. BPDCN may involve multiple
sites, commonly skin, bone marrow (BM), peripheral blood
(PB) and lymph nodes (LN). Based on literature reports of
limited cases, over 50 % of BPDCN have chromosomal ab-
normalities, but no single chromosomal change has been
shown to be diagnostic of this entity. The common
chromosomal aberrations in BPDCN reported previously
include abnormalities involving chromosomes 5q (72 %),
12p (64 %), 13q (64 %), 6q (50 %), 15q (43 %), and 9
(usually monosomy 9, 28 %) [4, 6]. Aberrations of 12p are
among the most common findings in BPDCN.
In this report, we present a case of BPDCN with
complicated chromosomal abnormalities involving
chromosomes 12 and 22 and resulting in simultaneous
partial deletion of ETV6 and EWSR1. These findings
were identified in the BM of a patient with BPDCN in
the absence of morphologic, immunohistochemical, or
flow cytometry evidence of BPDCN. We also conduct a
literature review of conventional cytogenetic findings in
BPDCN.
Case presentation
The patient is a previously healthy 44-year-old man
who presented with a painless enlarging mass in his
left groin. He was observed initially for three months
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and eventually was referred for an excisional lymph
node biopsy. Histologic examination showed a high-
grade malignant neoplasm that was diagnosed as
BPDCN. He was then referred to our institution. BM
evaluation included a trephine biopsy and aspiration.
There was no evidence of BPDCN in BM by morphology
or immunohistochemistry. Flow cytometry was also nega-
tive for BPDCN in BM. However, conventional cytogen-
etic analysis performed on the BM aspirate sample
showed karyotypic aberrations involving chromosomes 12
and 22, which were further characterized by fluorescence
in situ hybridization (FISH) analysis (see details below).
The patient was treated with a hyper-CVAD-Bortezomib
regimen (hyperfractioned cyclophosphamide, vincristine,
doxorubicin, dexamethasone alternating with high dose of
methotrexate and cytarabine, plus bortezomib) regimen.
He also received prophylactic intrathecal chemotherapy




Conventional chromosomal analysis (karyotyping) was
performed on G-banded metaphase cells prepared from
unstimulated 24-h and 48-h bone marrow cultures as de-
scribed previously [7]. Twenty metaphases (10 from each
culture) were analyzed. The chromosomal abnormalities
were reported according to the International System for
Human Cytogenetic Nomenclature 2013 (ISCN2013)
guidelines [8]. Out of 20 metaphases analyzed, 10 exhib-
ited structural abnormalities involving chromosomes 12
and 22.
Fluorescence in situ Hybridization (FISH) analysis
The following FISH probes were applied in this study:
Vysis ETV6 Break Apart (BAP) FISH probe and Vysis
EWSR1 BAP FISH probe (Abbott Molecular, Des Plaines,
IL) were used for interphase, metaphase and tissue FISH
tests. The VysisMYC BAP FISH probe (Abbott Molecular,
Des Plaines, IL) was used for both interphase and tissue
FISH tests. The Vysis LSI BCR/ABL ES Dual Color Fusion
probe (Abbott Molecular, Des Plaines, IL) was used for
interphase FISH tests, whereas the Aquarius Whole
Chromosome Painting (WCP) probes for chromosomes
12 and 22 (Cytocell, Tarrytown, NY) were used for
metaphase FISH only. All probes were thoroughly vali-
dated in accordance with the American College of
Medical Genetics and Genomics (ACMGG) guidelines.
Interphase FISH performed on unstimulated cultured
cells from BM sample using the ETV6 BAP probe showed
that about 25 % of cells had a one-red-one-fusion (1R1F)
signal pattern, indicating an ETV6 gene rearrangement
with a partial deletion of the 3′ETV6 (green signal). A sep-
arate interphase FISH analysis using the EWSR1 BAP
probe showed that almost the same percentage of cells
had a one-green-one-fusion (1G1F) signal pattern, dem-
onstrating an EWSR1 gene rearrangement with a partial
deletion of the 5′EWSR1 (red signal). Mapping back to
previously G-banded and karyotyped metaphases showed
that the existing 5′ETV6 (red signal) is located at the long
arm of the abnormal chromosome 22, whereas the exist-
ing 3′EWSR1 (green signal) is located at the short arm of
the abnormal chromosome 12 (Fig. 1). Whole chromo-
some painting (WCP) further confirmed the origins as
abnormal chromosomes 12 and 22 (images not shown).
Therefore, the results of conventional cytogenetic analysis
and FISH analysis suggest that a translocation between
12p and 22q occurred. This was likely followed by a peri-
centric inversion of the abnormal chromosome 12 result-
ing in a partial deletion of both 3′ETV6 and 5′EWSR1.
These two abnormal chromosomes are described as
der(12)t(12;22)(p13;q12)del(22)(q12q12)inv(12)(p13q24.1)
and der(22)t(12;22)del(12)(p13p13).
Due to the complexity of these chromosomal aberra-
tions and a low resolution of the available karyogram,
the derivative chromosomes were drawn by using the
online CyDAS software [9], and the corresponding
FISH signals were labeled (Fig. 2). Neither MYC gene
rearrangement nor BCR/ABL fusion were detected in
the BM specimen.
Interphase FISH performed on the formalin-fixed,
paraffin-embedded LN sample showed that 90 % of cells
had the same EVT6 and EWSR1 signal patterns as
detected in the BM (images not shown). Therefore, the
same chromosomal aberrations have been confirmed on
FFPE tissues of the LN biopsy as well. We combined
morphologic and FISH analysis as described previously
[10, 11] to further characterize the type of BM cells
carrying the chromosomal aberrations described above.
As shown in Fig. 3, all cells in the BM specimen were
morphologically and immunopheno typically normal
(Fig. 3a, H.E. staining image), but FISH tests using ETV6
BAP probe on the same slide detected a positive signal
pattern for ETV6 rearrangement and partial deletion of
3′ETV6 (Fig. 3b, FISH test image).
Morphologic and flow cytometry immunophenotypic
analyses
Morphological examination of hematoxylin-eosin-stained
histologic sections of BM biopsy specimen and Roma-
nowsky stained PB and/or BM aspirate smears did not
show any morphologic evidence of disease. Cell markers in-
cluding CD2, CD4, CD5, CD7, CD13, CD14, CD15, CD19,
CD22, CD33, CD34, CD36, CD38, CD45, CD56, CD64,
CD117, CD123, HLA-DR (Becton-Dickinson Biosciences,
San Jose, CA) were assessed by flow cytometry immuno-
phenotyping [6, 10, 11]. No evidence of a CD123 positive,
CD4 positive cell population was detected.







chr 12 der(12) der(22) chr 22
Fig. 2 Karyograms of normal chromosomes 12 and 22, abnormal chromosomes 12 (der(12)) and 22 (der922)) drawn by using CyDAS program [9]







Fig. 1 Mapping back to G-banded Metaphases with ETV6 BAP and EWSR1 BAP respectively. ETV BAP FISH (a-c): a. Metaphase FISH exhibiting an
intact ETV6 (yellow signal) on a normal chromosome 12 and 5′ETV6 (red signal) on an abnormal chromosome 22; b. Metaphase; c. Karyotype.
EWSR1 BAP FISH (d-f): d. Metaphase FISH exhibiting an intact EWSR1 (yellow signal) on a normal chromosome 22 and 3′EWSR1 (green signal) on
an abnormal chromosome 12; e. Metaphase; f. Karyotype
Tang et al. Molecular Cytogenetics  (2016) 9:23 Page 3 of 10
Molecular testing
The BM sample was screened for somatic mutations using
a clinically validated next-generation sequencing (NGS)-
based 28-gene assay [6]. The genes in this panel included:
ABL1, ASXL1, BRAF, DNMT3A, EGFR, EZH2, FLT3,
GATA1, GATA2, HRAS, IDH1, IDH2, IKZF2, JAK2, KIT,
KRAS, MDM2, MLL, MPL, MYD88, NOTCH1, NPM1,
NRAS, PTPN11, RUNX1,TET2,TP53, and WT1. No muta-
tions in any of the genes assessed were detected in the BM
sample.
Discussion
We report the first case of BPDCN that carried a transloca-
tion between chromosomes 12 and 22, followed by a subse-
quent pericentric inversion of the abnormal chromosome
12, and that resulted in a simultaneous partial deletion of
3′ETV6 and 5′EWSR1. Based on separate locations of the
remaining 5′ETV6 and 3′EWSR1 (Fig. 2), there is unlikely
an ETV6/EWSR1 fusion gene present in this case. Import-
antly, these aberrations were detected in BPDCN cells in
the LN as well as in hematopoietic precursors in a BM
samples that had no evidence of involvement by BPDCN.
The cytogenetic characterization of BPDCN is not
well established, mostly due to the rarity of this disease
and its relatively recent recognition and diagnostic
characterization. In one of the largest cohorts to date,
Leroux et al. [4] reported that 14 of 21 cases of CD4 +
CD56+ DC2 acute leukemia/BPDCN had an abnormal
karyotype, which was further characterized using inter-
phase FISH, metaphase FISH, whole chromosome
painting (WCP) and spectral karyotyping (SKY). These
analyses delineated six major chromosomal targets for
this disease, including 5q (72 %), 12p (64 %), 13q
(64 %), 6q (50 %), 15q (43 %) and 9 (28 %). Additional
smaller studies and reports showed similar findings.
In Table 1, we have summarized a total of 46 BPDCN
cases with abnormal karyotypes, 45 from previous literature
reports [4, 6, 12–28] plus the case presented in this report.
A minor modification has been made to some of the cases
from previous literature reports in order to follow the ISCN
2013 nomenclature guidelines [8] as well as to integrate all
findings derived by means other than conventional analysis
(e.g., FISH and SKY) into the description of an abnormal
karyotype. A similar number of BPDCN cases with possible
chromosomal abnormalities are not included in this table,
mainly due to a lack of complete karyotype description in
these literature [29–37]. In addition, our analysis has fo-
cused on cytogenetic alterations and does not include mu-
tations in genes such as TET2 that have been shown to be
present in a sizeable subset of BPDCN [6, 38]. The muta-
tional landscape of BPDCN is beyond the scope of this
review.
Thirty-four of 46 (74 %) cases of BPDCN reported had a
complex karyotype (at least 3 chromosomal aberrations
including at least one structural aberration), indicating
that multiple recurrent chromosomal abnormalities are
very common. The frequency of involvement of each
chromosome is listed in Table 2. Of interest, our literature
review identified the same six major chromosomal aber-
rancies reported by Leroux et al. [4], but with a deviant
frequency for each chromosome as follows: 6 (20/46,
43 %), 12 (20/46, 43 %), 13 (20/46, 43 %), 9 (17/46, 37 %),
15 (17/46, 37 %), and 5 (15/46, 33 %). Whereas numerical
A B
Fig. 3 Combined morphology and FISH analysis on the same bone marrow slide to further characterize the type(s) of cells carrying the
chromosomal aberrations described above. a H.E. staining image (100×) showing all cells morphologically normal; b FISH test using ETV6 BAP
probe showing that in the same field as the H.E. staining image, majority of the cells have exhibited two-fusion/yellow signals pattern, except
two maturing myelocytes (pointed with green arrows in both a and b) showing one-fusion/yellow, one-green signals pattern, indicating deletion
of one copy of the 3′ETV6 (red signal)
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Table 1 A summary of abnormal karyotypes in BPDCN cases reported in literatures
Case# Abnormal Karyotypesa Authors
1 44,X,-Y,der(1)t(Y;1)(q12;q?21),der(3)t(1;3)(p11;q?),del(5)(?q33q35),der(6)t(1;6)(q22;q?)t(1;8)(q?;q?),
der(12)t(1;12)(?;p11),r(13)[7]/46,XY[8]
Leroux et al. [4]
2 46,XX,del(5)(q13q33)[2]/42,idem,der(1)t(1;8)(?q43;?),dup(2)(?q35q37),-9,der(12)(?),
-13,-15,der(20;21)(?p11;?q22),der(21;21)(q21;q11)ins(21;12)(q11;?)[20]/46,XX[3]
Leroux et al. [4]
3 84 ~ 87,XX,del(X)(q24),del(X)(q24),add(2)(q3?),der(2)(?),+del(4)(q23),+del(5)(q14),+del(5)
(q14q23),add(6)(q?),-9,-11,del(12)(p12),-13,-13,-14,-15,-15,-17,-17,-18,+r(?),+1 ~ 3mar[cp11]/46,XX[4]
Leroux et al. [4]
4 45,XY,del(5)(q3?1q3?5),der(7)t(7;12)(?p11.2;q11),-12[3]/46,XY[10] Leroux et al. [4]
5 45,XY,+5,der(5)t(5;11)(p10;?),der(5)t(5;11)(p10;?),add(6)(q?22),del(11)(q14q23),-13,-15[4]/46,XY[2] Leroux et al. [4]
6 44,XX,del(3)(p21),-5,-12,-13,add(17)(p11),-18,-19,+3mar[27]/46,XX[2] Leroux et al. [4]
7 48,XY,+6,add(6)(q10),add(6)(q10),add(9)(p24),der(12)t(1;12)(q22;p13),+21[2]/46,XY[13] Leroux et al. [4]
8 43,XY,t(3;6)(p25;q2?3),der(7)t(7;19)(p21;q10),-9,der(12)t(5;12)(?;p11),-13,-19[10] Leroux et al. [4]
9 46,XY,del(2)(p2?1),add(8)(q2?4),del(13)(q1?3q2?1)[31]/47,idem,+mar[10] Leroux et al. [4]
10 46,XX,del(12)(p12p13)[9]/46,XX[2] Leroux et al. [4]
11 45,XX,del(5)(q13q34),?inv(11)(p11q21),der(15;18)(q10;q10)[15]/44,idem,-22,
dmin[2]/88,idemx2,del(6)(q16)[2]/46,XX[1]




Leroux et al. [4]
13 44,XY,-9,-13[8]/88,idemx2[18]/46,XY[5] Leroux et al. [4]
14 49,XY,+6,t(6;8)(p21;q24),+r(12),+20[6]/49,idem,inv(15)(q1?4q2?3),t(16;16)(q?;q?)[6]/49,idem,t(3;5)(q?21;q?31)[5] Leroux et al. [4]
15 46,XX,del(5)(q13q33)[2]/42,idem,-9,-12,-13,-15,-21,+3mar[20]/46,XY[2] Petrella et al. [12]
16 43,XX,der(1)t(1;15)(p22;q14),der(2)t(2;6;9)(p23;?;?),del(5)(q12q34),del(6)(q21),-9,-12,-13[12]/46,XX[17] Petrella et al. [12]
17 45,X,-Y[2]/46,XY[36] Petrella et al. [12]







Alayed et al. [6]
20 47 ~ 49,XY,+8,+8,del(13)(q12q14),+21[cp4]/46,XY[7] Alayed et al. [6]
21 44 ~ 47,XX,del(3)(p21),del(6)(q13q23),+1 ~ 6mar[cp5]/46,XX[17] Alayed et al. [6]
22 46,XY,t(1:9)(p36.1;q34)[7] Alayed et al. [6]
23 45,XY,del(12)(p13),-13[7] Alayed et al. [6]
24 49,XY,+der(?)t(Y;?)(q12;?),+21,+mar[17]/46,XY[3] Bayerl et al. [13]
25 45,XY,t(2;5)(p23;q35),–9,t(12;17)(p11;p11)[9]/44,XY,idem,–13,add(15)(p11) [13] Bayerl et al. [13]
26 46,XY,del(6)(q23),del(17)(q21)[23]/46,XY[3] Bayerl et al. [13]
27 37 ~ 38,XX,add(3)(p25),del(6)(q21q25),–7,add (7)(p22),–8,i(8)(q10),–9,–10,add
(11)(p15),i(11)(q10),–12,–13,–15,-17,add(19)(p13)[cp12]/46,XX[3]
Rakozy et al. [14]





30 46,XY,del(6)(q21q25)[12]/46,XY,del(12)(p11.2p12)[4]/46,XY,add(11)(q23)[5] Wilson and Medeiros
[16]
31 45,X,-Y[17] Patel et al. [17]
32 47,XX,t(7;9)(p15;p24),+8 Goren Sahin et al. [18]
33 44,XY,del(5)(q13),-13,der(13)t(11;13)(q12;q32),-15 Brody et al. [2]
34 45,XY,del(7)(p12),del(9)(q12q22),-10,del(11)(q21) Anargyrou et al. [19]
35 45,XY,der(9)t(1;9)(p22;p13),del(11)(q21),−15[10]/46XY[4] Karube et al. [20]
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aberrations were detected frequently for chromosomes 13
(18/20, 90 %), 9 (12/17, 71 %) and 15 (9/17, 53 %), we
observed structural aberrations more commonly in chro-
mosomes 6 (20/20, 100 %), 5 (14/15, 93 %) and 12 (16/20,
80 %). Further analysis examining the breakpoints and
consequences of the above mentioned structural aberra-
tions has revealed that 5q-, 6q- and/or 12p- were common
with a frequency of 93 % for 5q-, 90 % for 6q-, and 88 %
for 12p-. This phenomenon has been observed by Lucioni
et al. [29] in a study of 21 BPDCN cases by using an
array-based comparative genomic hybridization (aCGH)
assay as well as by other research groups [5, 30–34]. We
have an ongoing project studying the correlation between
the complexity of the karyotype and outcome of this dis-
ease in patients who had been seen and followed-up in
our institute.
The 12p- is considered to be one of the most com-
mon structural aberrations in BPDCN. Two major tar-
get genes/loci located on the 12p have been identified
as potential hotspots in the literature, CDKN1B and
ETV6. The CDKN1B gene is located on 12p13.1p12
spanning from 12,717,270 to 12,722,383 (5114 bp,
GRCh.38.p2). The protein encoded by this gene, p27
(also known as KIP1), is a kinase inhibitor and an atyp-
ical tumor suppressor through regulation of the activity
of cyclin-dependent kinases (Cdks). Therefore, dysfunc-
tion of CDKN1B plays a role in pathogenesis and me-
tastasis of multiple cancers, such as breast cancer,
prostate cancer and leukemia [39]. Loss of the CDKN1B
locus has been reported in over 60 % of BPDCN cases,
including cases with a normal karyotype [5, 29–32].
Due to the size of this gene, its loss has been detected
only by array comparative genomic hybridization assay
in the literature. Immunohistochemistry studies have
further confirmed weak expression of p27 protein in al-
most all these cases. ETV6, also known as TEL, THC5
or TEL/ABL gene, is located on 12p13 spanning from
11,649,854 to 11,895,402 (245,549 bp), less than 1 Mb
apart from CDKN1B. Both genes were simultaneously
lost in the cases mentioned above. ETV6 is a gene with
the characteristics of a tumor suppressor gene and
encodes an ETS family transcription factor. ETV6 has
been shown to play an important role in the pathogen-
esis of various types of leukemia, mostly through form-
ing fusion genes with over 40 different translocation
partners [40, 41]. In BPDCN (Tables 1 and 2), over
40 % of cases had a structural abnormality involving
12p, very likely resulting in a 12p- at various break-
points and including a deletion of CDKN1B and ETV6
in most cases by roughly analyzing the breakpoints.
Some of these cases might have had an ETV6 re-
arrangement as well. ETV6 (approximately 250 Kb of
size) is a good target for FISH testing and other studies
have demonstrated a deletion or rearrangement of
ETV6 by FISH testing in BPDCN cases with or without
an obvious 12p-; the deletion can be monoallelic or
biallelic [5, 29]. Therefore, 12p-, more specifically a de-
letion or rearrangement of CDKN1B and/or ETV6, may
deserve further investigations as potential markers of
BPDCN.
Chromosome 22 abnormalities appear to be rare in
BPDCN (5/46, 11 %) (Tables 1 and 2). Three cases re-
ported so far had a numerical change and 2 other
cases (including the one in this study) had a structural
aberration of chromosome 22. However, chromosomal
aberrations involving a chromosome 22 might have
been underestimated, most likely due to technical lim-
itations including: size of chromosome 22 (one of the
Table 1 A summary of abnormal karyotypes in BPDCN cases reported in literatures (Continued)
36 69,XXX,t(1;6)(q21;q23),der(6)t(1;6),add(7)(p11) × 2,−9,+12,add(12)
(p11) × 2,−15,−15,−15,−16,+20,−22,+1 ~ 4mar[3]/46XX[17]
Karube et al. [20]
37 44,XX,t(1;6)(q31;q25)[20] Rossi et al. [21]
38 45,XY,-1,-3,add(6)(q?),+mar[20] Rossi et al. [21]
39 45,XX,-13/45,XX,-22/46,XX Eguaras et al. [22]
40 46,XY,add(9)(p24),del(11)(q22) Chang et al. [23]
41 47,X,-Y,t(6;8)(p21;q24),+add(7)(p11.2),+der(8)t(6;8),+20[17]/46,XY (LN cells) and 48,X,-Y,t(6;8)(p21;q24),+add
(7)(p11.2),+der(8)t(6;8),+20[5]/49,idem,+mar[2]/49,idem,der(8)t(6;8),?t(9;15)(p22;q15),+mar[2]/46,XY[3] (BM cells)
Nakamura et al. [24]
42 46,XY,del(12)(p12),del(17)(p11)[17]/46,XY[13] Agapidou et al. [25]
43 44,XY,der(1)t(1;1)(q42;q11),t(7;12)(p13;p13),-13,-17,der(19)t(17;19)(q21;p13)[8]/46,XY[11] DiGiuseppe et al. [26]
44 45,XY,der(7)t(1;7)(q11;p22),der(12;15)(q10;q10),add(13)(q12)[7]/44,idem,-9[4]/44,
idem,del(3)(p25),-9[3]/46,XY[6]
Kameoka et al. [27]
45 45,XY,der(3;7)(q10;q10),t(6;19)(p21.1;p13.3),t(8;18)(q24.1;q21.1) [16]/46,XY[4] Yu et al. [28]
46 46,XY,der(12)t(12;22)(p13;q12)del(22)(q12q12)inv(12)(p13q24.1),der(22)t(12;22)del(12)(p13p13)[10]/46,XY[10] this study
aIn some cases, current description of abnormal karyotypes may be slightly different from their previous literature reports. A minor modification has been made in
order to follow the ISCN 2013 nomenclature guidelines as well as to integrate all findings by other means than conventional analysis (e.g., FISH and SKY) into the
description of an abnormal karyotype
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Table 2 Distribution of numerical and structural chromosomal abnormalities in BPDCN
Chr. Total (%)a Numerical aberrations Structural aberrations
X 1 (2 %) (n = 0) del(X)(q24) (n = 1)
Y 6 (13 %) loss (n = 5) der(?)t(Y;?); der(1)t(Y;1)(q12;q?21); t(Y;14)(q11;p11) (n = 3)
1 12 (26 %) monosomy (n = 1) del(1)(p22); del(1)(q42q44); der(1)t(Y;1)(q12;q?21); der(1)t(1;1)(q42;q11);
t(1;6)(p21;p36.3)t(1;6)(q21;q23); t(1;6)(q31;q25); t(1;8)(q?;q?); der(1)t(1;8)(?q43;?); t(1:9)(p36.1;q34);
t(1;10)(p36.1;p13); t(1;12)(?;p11); t(1;12)(q22;p13); der(1)t(1;15)(p22;q14) (n = 13)
2 7 (15 %) (n = 0) del(2)(p2?1); add(2)(q37); add(2)(q3?); dup(2)(?q35q37); der(2)(?); der(2)t(2;3)(q21;q27); t(2;5)(p23;q35);
der(2)t(2;5)(p?;?); der(2)t(2;6;9)(p23;?;?) (n = 7)
3 11 (24 %) monosomy (n = 1) del(3)(p21); add(3)(p25); der(3)t(1;3)(p11;q?); t(3;5)(q?21;q?31); t(3;6)(p25;q2?3); der(3;7)(q10;q10);
der(3)t(3;8)(p25;q24)t(2;3) (n = 11)
4 1 (2 %) del(4)(q23) (n = 1)
5 15 (33 %) monosomy (n = 2);
trisomy (n = 2)
del(5)(p13); del(5)(q11.2q33); del(5)(q12q34); del(5)(q13q33); del(5)(q13q34); del(5)(q13); del(5)(q14);
del(5)(q14q23); del(5)(?q33q35); add(5)(q35); t(2;5)(p23;q35); t(3;5)(q?21;q?31); der(5)t(5;11)(p10;?);
der(5)t(5;13)(q21;q?) (n = 14)
6 20 (43 %) monosomy (n = 1);
trisomy (n = 2)
add(6)(p11.2); add(6)(q?); add(6)(q10); del(6)(q13q21); del(6)(q13q23); del(6)(q16); del(6)(q21);
del(6)(q21q25); del(6)(q23); der(6)t(1;6)(q22;1q?); add(6)(q?22); t(1;6)(q21;q23);
t(1;6)(p21;p36.3)t(1;6)(q31;q25); der(6)t(2;6); t(3;6)(p25;q2?3); t(6;8)(p21;q24); t(6;18)(q2?2;q22);
t(6;19)(p21.1;p13.3) (n = 20)
7 11 (24 %) monosomy (n = 1);
trisomy (n = 1)
add(7)(p11); add (7)(p22); der(7)t(1;7)(q11;p22); der(7)del(p11.2)del(7)(q11.2q31); der(3;7)(q10;q10);
t(7;9)(p15;p24); der(7)t(7;12)(?p11.2;q11); t(7;12)(p13;p13); der(7)t(7;12)(q22;q13);
der(7)t(7;19)(p21;q10) (n = 10)
8 11 (24 %) monosomy (n = 1);
trisomy/tetrasomy
(n = 3)
i(8)(q10); add(8)(q2?4); t(6;8)(p21;q24); der(8)t(6;8)(p21;q24); t(8;14)(q24.1;q32);
t(8;18)(q24.1;q21.1) (n = 9)
9 17 (37 %) monosomy (n = 12) add(9)(p24); del(9)(q12q22); der(9)t(1;9)(p22;p13); t(1:9)(p36.1;q34); t(7;9)(p15;p24);
t(9;15)(p22;q15) (n = 7)
10 3 (7 %) monosomy (n = 2) t(1;10)(p36.1;p13) (n = 1)
11 10 (22 %) monosomy (n = 1);
trisomy (n = 1)
add (11)(p15); i(11)(q10); del(11)(q14q23); del(11)(q21); del(11)(q22); del(11)(q23); add(11)(q23);
inv(11)(p11q21); del(11)(q13q23) (n = 9)
12 20 (43 %) monosomy (n = 3) add(12)(p11); add(12)(p11.2); der(12)(?); del(12)(p11.2p12); del(12)(p12); del(12)(p12p13);
del(12)(p13); der(12)t(1;12)(?;p11); der(12)t(1;12)(q22;p13); der(12)t(5;12)(?;p11); t(7;12)(p13;p13);
t(12;17)(p11;p11); r(12); der(12)t(12;22)(p13;q12)del(22)(q12q12)inv(12)(p13q24.1) (n = 16)
13 20 (43 %) monosomy (n = 18) add(13)(q12); del(13)(q12q22); del(13)(q12q14); del(13)(q1?3q2?1); der(13)t(11;13)(q12;q32);
der(13)t(13;21)(q10;q10) (n = 4)
14 3 (7 %) monosomy (n = 1) add(14)(q32); der(14)t(Y;14)(q11;p11) (n = 2)
15 17 (37 %) monosomy (n = 9) add(15)(p11); inv(15)(q1?4q2?3); der(15)t(1;15)(p?;q21); ?t(9;15)(p22;q15); der(12;15)(q10;q10);
der(15;18)(q10;q10); r(15) (n = 8)
16 4 (9 %) monosomy (n = 1);
trisomy (n = 1)
del(16)(p11.1); t(16;16)(q?;q?) (n = 2)
17 9 (20 %) monosomy (n = 3);
trisomy (n = 1)
add(17)(p11); del(17)(p11); add(17)(p13); del(17)(q21); t(12;17)(p11;p11) (n = 6)
18 6 (13 %) monosomy (n = 2);
trisomy (n = 1)
add(18)(q11.2); t(6;18)(q2?2;q22); der(15;18)(q10;q10) (n = 3)
19 7 (15 %) monosomy (n = 2) add(19)(p13); add(19)(p13.3); der(19)t(1;19)(q23;p13); der(19)t(3;19)(p21;q13); t(6;19)(p21.1;p13.3);
t(7;19)(p21;q10); der(19)t(17;19)(q21;p13) (n = 6)
20 4 (9 %) trisomy (n = 3) der(20;21)(?p11;?q22) (n = 1)
21 6 (13 %) monosomy (n = 1);
trisomy (n = 4)
der(20;21)(?p11;?q22); der(21;21)(q21;q11)ins(21;12)(q11;?) (n = 1)
22 5 (11 %) monosomy (n = 3) der(22)t(12;22)del(12)(p13p13); i(22)(q10) (n = 2)
M 11 (24 %) (n = 0) (n = 11)
R 4 (9) (n = 0) r(12); r(13); r(15); r(?) (n = 4)
aThe majority of cases had a complex karyotype, containing multiple numerical and structural aberrations. M: marker chromosome; R: ring chromosome
Tang et al. Molecular Cytogenetics  (2016) 9:23 Page 7 of 10
smallest chromosomes with limited banding patterns);
extremely low karyotyping resolution in cancer cases;
and high percentage of complex karyotypes and
marker chromosomes in BPDCN cases. In our case, a
EWSR1 rearrangement with a deletion of the 5′EWSR1
was detected. EWSR1 rearrangement has been re-
ported mostly in soft tissue tumors [42–44], also
rarely in hematologic malignancies [37, 45, 46], but
only in one BPDCN case previously [37]. The EWSR1
gene has a large number of fusion partners, including
members of the ets family, such as FLI1, ERG and
ETV1 but not ETV6 [42–44]. As mentioned above, ac-
cording to the locations of the remaining 5′ETV6 and
3′EWSR1, an ETV6/EWSR1 fusion can be excluded in
this case. However, due to occurrence of inversion in
the affected chromosome 12 and partial deletion of
both 3′ETV6 and 5′EWSR1, gene fusions between
ETV6 and a partner gene on 22q as well as between
EWSR1 and a partner gene on 12q cannot be com-
pletely excluded. The biological implications of these
EWSR1 aberrations are unknown.
Clinical manifestation of BPDCN vary among patients.
Most BPDCN patients present with one or more skin le-
sions with or without BM or LN involvement. The patient
in this study presented with progressive LN enlargement
as the only notable finding. His BM tested by multiple
means was negative for BPDCN involvement. However,
the same chromosomal aberrations were detected in his
LN with BPDCN as well as BM without BPDCN. Com-
bined morphologic and FISH analysis further confirmed
that the BM cells carrying the chromosomal aberrations
were morphologically normal. One explanation is that the
chromosomal abnormalities in our case may constitute an
initiating event within a hematopoietic stem cell precursor
and that a second hit in a cell capable of acquiring pheno-
typic features of plasmacytoid dendritic cells is required
for BPDCN to develop (Fig. 3). This hypothesis is intri-
guing particularly since a link between BPDCN and mye-
loid malignancies has long been observed, even though
the pathogenic link between these entities remains un-
known. Indeed, many patients with BPDCN have shown
to develop acute myeloid leukemia (AML) [3, 6, 28]. In
addition, a sizeable subset of BPDCN involving the BM
has been reported to be associated with myelodysplastic
features at the morphologic and/or cytogenetic levels [6].
Another explanation is that a minimal BM dissemination
of BPDCN and growth advantage of neoplastic cells in ex
vivo culture may contribute to the results in our case.
In summary, over 50 % of BPDCN cases have chromo-
somal abnormalities, with more than 70 % of BPDCN
cases exhibiting a complex karyotype. Monosomy 13/
13q-, 12p-, 6q-, monosomy 15/15q-, 5q- and monosomy
9 are characteristic chromosomal abnormalities in
BPDCN. The 12p- is one of the most common structural
aberrations in BPDCN, and a deletion/rearrangement of
CDKN1B and/or ETV6 on 12p is often detected. These
two genes, together with EWSR1 on 22q, may deserve
further investigations as potential BPDCN markers.
Conclusion
This is the first case of BPDCN that carried a translocation
between chromosomes 12 and 22, followed by a subsequent
pericentric inversion of the abnormal chromosome 12, and
that resulted in a simultaneous partial deletion of 3′ETV6
and 5′EWSR1. Analyzing all 45 BPDCN cases with abnor-
mal karyotypes available in the literature plus this case, 6
major chromosomal targets are identified in BPDCN: chro-
mosomes 6 (20/46, 43 %), 12 (20/46, 43 %), 13 (20/46,
43 %), 9 (17/46, 37 %), 15 (17/46, 37 %), and 5 (15/46,
33 %). Deletion of 12p (12p-) is one of the most common
structural aberrations, and the ETV6 and CDKN1B on 12p
deserve further investigations as potential markers of
BPDCN.
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